Penalizing FDA for Expanding Mifepristone Access 7

Agriculture, Rural Development, Food and Drug Administration (FDA), and Related Agencies Appropriations Act, 2024, H.R.4368. Good (R-VA) amendment to reduce to $1 the salary of the Director of the Office of Regulatory Policy at the FDA as part of ongoing attempts to limit access to mifepristone by targeting trained experts for their scientific and medical decision making. A vote for reproductive freedom was against the amendment.

This measure negatively impacts reproductive freedom.

H.R.4368

Voting Record

State/Territory:

Chamber:

Party:

Votes:

Name	State/Territory	Chamber	Party	How they voted yea Vote for/in favor of nay Vote against — Abstained, absent, ineligible, present, resigned or deceased L Leader switched vote to preserve right to file a motion to reconsider S The speaker exercised their discretion not to vote
Diana DeGette	Colorado	House	Democratic	nay
Rosa DeLauro	Connecticut	House	Democratic	nay
Suzan DelBene	Washington	House	Democratic	nay
Chris Deluzio	Pennsylvania	House	Democratic	nay
Mark DeSaulnier	California	House	Democratic	nay
Scott DesJarlais	Tennessee	House	Republican	yea
Mario Diaz-Balart	Florida	House	Republican	yea
Debbie Dingell	Michigan	House	Democratic	nay
Lloyd Doggett	Texas	House	Democratic	nay
Byron Donalds	Florida	House	Republican	yea
John Duarte	California	House	Republican	yea
Jeff Duncan	South Carolina	House	Republican	yea
Neal Dunn	Florida	House	Republican	yea
Chuck Edwards	North Carolina	House	Republican	nay
Jake Ellzey	Texas	House	Republican	yea
Tom Emmer	Minnesota	House	Republican	yea
Veronica Escobar	Texas	House	Democratic	nay
Anna Eshoo	California	House	Democratic	nay
Adriano Espaillat	New York	House	Democratic	nay
Ron Estes	Kansas	House	Republican	yea
Dwight Evans	Pennsylvania	House	Democratic	nay
Mike Ezell	Mississippi	House	Republican	yea
Pat Fallon	Texas	House	Republican	yea
Randy Feenstra	Iowa	House	Republican	yea
Drew Ferguson	Georgia	House	Republican	yea